Related references
Note: Only part of the references are listed.Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H. Wei et al.
BLOOD (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
Courtney D. DiNardo et al.
LANCET HAEMATOLOGY (2020)
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Andrew H. Wei et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology
Oliver A. Cornely et al.
MYCOSES (2019)
Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia
Caitlin R. Rausch et al.
BLOOD (2019)
Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial
Abhishek Maiti et al.
BLOOD (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial
Nicholas J. Short et al.
LANCET HAEMATOLOGY (2019)
Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents
Ibrahim Aldoss et al.
BLOOD ADVANCES (2019)
Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update
Randy A. Taplitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Abhishek Maiti et al.
BLOOD (2018)
Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments
Suresh K. Agarwal et al.
CLINICAL THERAPEUTICS (2017)
A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis
Lena M. Biehl et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
William Blum et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
Ben De Pauw et al.
CLINICAL INFECTIOUS DISEASES (2008)
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia
Oliver A. Cornely et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
